Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 11/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PRKX | P51817 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | MST1R | Q04912 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644700 | 0.89 | HPGDS (0.42) | HPGDSMAPK1ROCK1ROCK2 | |
| SCHEMBL1644385 | 0.88 | MAOB (0.43) | HPGDS | |
| SCHEMBL1285252 | 0.85 | HPGDS (0.44) | HPGDSROCK1HDAC6PRKACAGSK3A | |
| SCHEMBL14377396 | 0.83 | HPGDS (0.48) | HPGDSROCK1HDAC6PRKACAGSK3A | |
| SCHEMBL1644611 | 0.83 | HPGDS (0.46) | HPGDSMAPK1ROCK1ROCK2HDAC6 | |
| SCHEMBL1643047 | 0.83 | NR1H4 (0.41) | HPGDSMAPK1ROCK1ROCK2 | |
| SCHEMBL1644603 | 0.82 | MEN1 (0.37) | HPGDSROCK1ROCK2 | |
| SCHEMBL1643215 | 0.82 | PDE2A (0.43) | — | |
| SCHEMBL1643659 | 0.80 | LMNA (0.40) | ROCK1ROCK2GSK3B | |
| SCHEMBL1643052 | 0.79 | HPGDS (0.42) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | HPGDS 427/4885MAPK1 1154/4885ROCK1 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.